Why MEDEZE Is Thailand's Trusted Stem Cell Bank

Why MEDEZE Is Thailand's Trusted Stem Cell Bank

MEDEZE GROUP is Thailand's first and only stem cell bank operating in strict compliance with the Thai Drug Act B.E. 2510 (1967) under the supervision of the Thai Food and Drug Administration (Thai FDA).

Our state of the art banking processes are engineered to meet pharmaceutical-grade standards, ensuring rigorous quality control across collection, processing, and long-term preservation. Guided by internationally recognized safety protocols, we support the future of regenerative medicine, disease treatment and longevity science, all while upholding the highest standards of patient safety and regulatory compliance.

Thailand's First Ministry of Public Health-Certified Stem Cell Bank

Cell Bank certificate issued to Medeze Group by the Department of Medical Sciences, Ministry of Public Health

1. Thailand's First and Only Stem Cell Bank Operating in Compliance with the Thai Drug Act

MEDEZE GROUP is Thailand's first and only stem cell bank operating in compliance with the Thai Drug Act. As the only stem cell banking company listed on the Stock Exchange of Thailand (SET), MEDEZE upholds the highest standards of corporate governance, transparency, and accountability, reinforcing the confidence of families who entrust us with their stem cells. Together, these milestones reflect our commitment to pharmaceutical-grade quality, regulatory compliance, and long-term safety in stem cell banking.

2. Internationally Recognized Quality Standards

Long before Thailand introduced official stem cell banking standards, MEDEZE had already established a quality management system certified to ISO 9001:2015 and earned AABB accreditation, demonstrating our commitment to internationally recognized standards in stem cell processing and preservation.

3. Proven Technology for Maximum Cell Quality

MEDEZE utilizes advanced technologies, including the AXP® AutoXpress® Platform and Cryopreservation, to help maximize cell recovery, maintain cell viability, and ensure precision throughout the collection, processing, and long-term storage process.

4. Comprehensive Stem Cell Banking Solutions

We provide preservation services for multiple cell sources, including cord blood, cord tissue, adipose tissue, hair follicle stem cells, and NK cells, allowing families to support a wide range of future healthcare and regenerative medicine possibilities through a single trusted provider.

5. Built for Long-Term Confidence

Every stem cell sample is processed, preserved, and monitored under strict quality control procedures, giving families confidence that their cells are stored safely and remain ready to support future medical advancements when needed.

6. A Trusted Partner for Future Healthcare

Stem cell banking is a lifelong investment. MEDEZE combines regulatory compliance, international certifications, advanced laboratory technology, and scientific expertise to help families prepare for the future with confidence.

Committed to Quality. Recognized Worldwide.

  • Thailand Top Entrepreneur Awards 2025: MEDEZE won Best Health Business of the Year, organized by Business+ Magazine with the University of the Thai Chamber of Commerce and SME D Bank
  • Asia Corporate Excellence & Sustainability Award 2024 (ACES Award): MEDEZE named Industry Champions of the Year
  • Business Person of the Year 2015 Award: Dr. Veerapol Khemarangsan honored in the medical sector at the Quality Persons of the Year 2015 ceremony by the Foundation of Science and Technology Council of Thailand (FSTT)

Our Journey of Excellence

A Leader in Sales and Innovation in the stem cell banking and immunotherapy technology industry, Backed by awards and continuous business growth spanning over 11 years.

2010

MEDEZE Is Founded

  • July 19, 2010: The company was officially registered under the name Bangkok Stem Cell Co., Ltd., with a registered capital of 3,000,000 Baht, divided into 30,000 shares with a par value of 100 Baht per share. The founding shareholders were Dr. Weerapol Khemarungsan, Associate Professor Dr. Rangsak Phalapai, and Dr. Jamras Sukulpaisal, with ownership distributions as follows: Dr. Weerapol Khemarungsan (50%), Mrs. Kittima Khemarungsan (33.33%), and Dr. Jamras Sukulpaisal (16.67%). The company was established to provide services related to the analysis, separation, cultivation, and storage of stem cells.
2010, The Beginning: Bangkok Stem Cell established

2011

Automated Cord Blood Processing

  • Implementation of Automated Sorting Technology: The company began using the AutoXpress automated machine, which can separate hematopoietic stem cells from umbilical cord blood. This technology reduces the risk of contamination and human error during the stem cell separation process.
2011, Advancing Automation: AutoXpress introduced for stem cell separation

2013

ISO 9001 and Adipose Stem Cell Banking

  • June 26, 2013: The Extraordinary General Meeting of Shareholders No. 1/2013 approved an increase in the company’s registered capital to 20,000,000 Baht. This was achieved by issuing 170,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
  • ISO 9001:2008 Certification: The company received the ISO 9001:2008 certification, recognizing its commitment to quality management standards.
  • Launch of Stem Cell Storage Services: The company began offering stem cell storage services using tissue extracted from the fat of individuals for stem cell banking.
2013, Quality Standards: ISO 9001:2008 certification

2015

Business Person of the Year 2015

  • October 1, 2015: The Extraordinary General Meeting of Shareholders No. 1/2015 approved an increase in the company’s registered capital to 30,000,000 Baht. This was achieved by issuing 100,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
2015, Supporting Growth: registered capital increased to THB 30 million

2016

Research and Development Arm

  • September 15, 2016: The Extraordinary General Meeting of Shareholders No. 3/2016 approved an increase in the company’s registered capital to 50,000,000 Baht. This was achieved by issuing 200,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
  • Establishment of Subsidiaries: Medeze Cosmeceuticals Co., Ltd.: Established with a registered capital of 1,000,000 Baht to engage in the sale of beauty products.
  • Medeze Research and Development Co., Ltd.: Established with a registered capital of 7,500,000 Baht to conduct experimental research and development in biotechnology.
2016, Advancing Research: research and development company established

2017

NK Cell Testing and ISO 22716

  • December 22, 2017: The Extraordinary General Meeting of Shareholders No. 2/2017 approved an increase in the company’s registered capital to 120,000,000 Baht. This was achieved by issuing 700,000 additional shares with a par value of 100 Baht per share. The capital increase supported business growth and was duly registered with the Ministry of Commerce.
  • Launch of Immune Cell (NK Cells) Testing Services: The company began offering services to test the potential of immune cells (NK Cells).
  • ISO 22716:2007 Certification: The company received the ISO 22716:2007 certification from MS Certification Services Pvt. Ltd.
  • Awards Received in 2017: Thailand Stem Cell Banking Growth Excellence Leadership Award from Frost & Sullivan.
  • Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
2017, NK Cell Testing Launched: assessing immune cell activity

2018

Becoming Medeze Group

  • December 6, 2018: The Extraordinary General Meeting of Shareholders No. 2/2018 approved an increase in the company’s registered capital to 150,000,000 Baht. This was achieved by issuing 300,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
  • Launch of the Medeze Application: Introduced the Medeze mobile application to provide customers with convenient access to information about their stem cell storage services.
  • Company Name Change: Changed the company’s name from Bangkok Stem Cell Co., Ltd. to Medeze Group Co., Ltd.
  • Awards Received in 2018: Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
2018, Becoming MEDEZE Group: company renamed and mobile app launched

2019

AABB Accreditation

  • Implementation of Advanced Technology: Began utilizing an automated mesenchymal stem cell expansion system (Quantum) to cultivate and expand stem cells from tissue within a short period.
  • AABB Accreditation: Received accreditation from the Association for the Advancement of Blood and Biotherapies (AABB) in the United States, recognizing the company’s compliance with rigorous operational standards for stem cell banking.
  • Awards Received in 2019: Southeast Asia Stem Cell Banking Growth Excellence Leadership Award from Frost & Sullivan.
  • Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
  • Thailand Brand Leadership Award from CMO Asia
2019, Technology and Standards: Quantum introduced and AABB accreditation

2020

Recognized for Innovation

  • December 15, 2020: The Extraordinary General Meeting of Shareholders No. 2/2020 approved an increase in the company’s registered capital to 185,000,000 Baht. This was achieved by issuing 590,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth. The registration of the capital increase with the Ministry of Commerce was completed on December 22, 2020.
  • Awards Received in 2020: Southeast Asia Stem Cell Banking Technology Innovation Leadership Award from Frost & Sullivan.
  • Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
2020, Innovation Recognition: technology award from Frost & Sullivan

2021

Expanding into NK Cells and Singapore

  • April 27, 2021: The Annual General Meeting of Shareholders for 2021 approved an increase in registered capital to 203,000,000 Baht. This was achieved by issuing 180,000 additional shares with a par value of 100 Baht per share. The capital increase was intended to support business growth. The registration of the capital increase with the Ministry of Commerce was completed on May 6, 2021.
  • September 2, 2021: The Extraordinary General Meeting of Shareholders No. 1/2021 approved an increase in registered capital to 225,000,000 Baht. This was done by issuing 220,000 additional shares with a par value of 100 Baht per share. The purpose of the capital increase was to prepare for listing on the Stock Exchange of Thailand (SET). The registration of the capital increase with the Ministry of Commerce was completed on September 15, 2021.
  • The meeting also approved a dividend payment of 20.00 Baht per share from the group’s retained earnings, totaling 40.60 million Baht in dividends distributed to shareholders.
  • Establishment of Subsidiaries: Medeze NK Co., Ltd.: Established with a registered capital of 20,000,000 Baht, supported by the Board of Investment (BOI) for the purpose of testing the potential of immune cells (NK Cells).
  • Medeze Treasury Pte. Ltd. (Singapore): Established with a registered capital of 1,820,000 Singapore dollars as an investment arm.
  • Medeze Group Pte. Ltd. (Singapore): Established with a registered capital of 2,400,000 Singapore dollars to conduct experimental research in natural sciences and operate medical laboratories.
  • Awards Received in 2021: Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
  • Southeast Asia Banking Company of the Year Award from Frost & Sullivan.
2021, Expanding into Singapore: subsidiaries established in Singapore

2022

Medeze Group Public Company Limited

  • July 19, 2022: At the Extraordinary General Meeting of Shareholders No. 1/2022, the group approved the following actions
  • Conversion to a Public Company The group transformed into a public company under the name Medeze Group Public Company Limited. This transformation was officially registered on July 27, 2022, to prepare for listing on the Stock Exchange of Thailand (SET).
  • Change in Par Value of Shares The par value of common shares was reduced from 100.00 Baht per share to 0.50 Baht per share. This adjustment increased the number of registered and issued shares from 450,000,000 to 600,000,000 shares, while the registered and paid-up capital remained unchanged. The change was officially registered with the Ministry of Commerce on July 27, 2022.
  • Increase in Registered Capital An additional 75,000,000 Baht in registered capital was approved, at a par value of 0.50 Baht per share, resulting in the issuance of 150,000,000 new shares. This raised the registered capital from 225,000,000 Baht to 300,000,000 Baht. These additional shares were allocated for the group’s initial public offering (IPO). More details can be found in Section 4, “Information Regarding the Offering of Securities.”
  • Approval for SET Listing The common shares of the group were approved for listing on the Stock Exchange of Thailand (SET).
2022, Becoming a Public Company: preparing to enter the capital market

2023

Southeast Asia Company of the Year

  • 8th September 2023, the Extraordinary General Meeting of Shareholders No. 1/2023 passed special resolutions to approve the following key matters:
  • Reduction of the Company’s registered capital by THB 75,000,000, equivalent to a reduction of 150,000,000 common shares at a par value of THB 0.50 per share, from the original registered capital of THB 300,000,000 to THB 225,000,000.
  • Increase of the Company’s registered capital by THB 175,000,000, equivalent to an increase of 350,000,000 common shares at a par value of THB 0.50 per share, from the previous registered capital of THB 225,000,000 to a new registered capital of THB 400,000,000. The meeting also approved the allocation of the newly issued shares to existing shareholders in proportion to their shareholding. The Company has received full payment for the capital increase.
  • The Company was awarded the Southeast Asia Stem Cell Banking Company of the Year 2023 by Frost & Sullivan.
2023, Building Strength: registered capital increased to THB 400 million

2024

IPO and Industry Champion

  • 21st March 2024, the 2024 Annual General Meeting of Shareholders resolved to approve the Group to proceed as follows
  • Increase the registered capital of common shares by 134,000,000 Baht at a par value of 0.50 Baht per share, totaling 268,000,000 shares, resulting in an increase of the registered capital from 400,000,000 Baht to 534,000,000 Baht. The allocation of the Group’s newly issued common shares shall not exceed 268,000,000 shares for offering to the general public for the first time (IPO), and the meeting approved the listing of the Group’s common shares on the Stock Exchange of Thailand (“SET”).
  • Currently, the Group has a total of 4 buildings used for its operations, comprising 1 head office building, 1 cell storage facility, 1 research and development building, and 1 Sales & Marketing building.
  • The Group has initiated renovations to the research and development building, including construction and preparation of cleanroom laboratories for the installation of a Robotic Cell Culture System, which is currently under renovation within the existing building.
  • The Board of Directors’ Meeting No. 5/2024 held on August 13, 2024, approved an interim dividend payment from retained earnings to existing shareholders prior to the Initial Public Offering (IPO) at the rate of 0.31 Baht per share, totaling 248 million Baht, based on the Company’s financial statements as of March 31, 2024.
  • Received the Industry Champions of the Year award from ACES Awards 2024
  • Received the Southeast Asia Stem Cell Banking Company of the Year award from Frost & Sullivan 2024
2024, Preparing a New Laboratory: for robotic cell culture systems

2025

15 Years and the ATMPs Sandbox

  • Established Medeze Hair Renaissance Co., Ltd. with a registered capital of 100,000,000 Baht to provide analysis, separation, cultivation and storage of hair follicle cells.
  • Signed a memorandum of understanding to operate a stem cell banking business in Manila, the Philippines, investing through its subsidiary Medeze Treasury Pte. Ltd. to establish a stem cell bank (Cell Banking Biotechnology).
  • Approved a joint investment and the establishment of a joint venture between the company, the public sector and the private sector to produce cell culture media. This is currently in progress.
  • Launched an ESG pilot project under the concept "The First Tangible Step Toward Sustainability in the Healthcare Services of the Future", developing the organization alongside environmental, social and governance responsibility.
  • Launched the Advanced Therapy Medicinal Products Sandbox (ATMPs Sandbox) together with Vachira Phuket Hospital and the Office of the Permanent Secretary, Ministry of Public Health, to raise standards toward a Medical Wellness Hub and future drug registration. The company was the only company selected for the pilot.
  • Joined JUMP+, a program that promotes value creation for listed companies.
  • Celebrated its 15th anniversary, "MEDEZE 15th Anniversary: Future of Thailand HEALTH Economy", continuing 15 years of stem cell innovation and moving the "Sandbox" project forward to bring medicine together toward a "HEALTH Economy".
  • Approved an interim dividend payment from retained earnings to shareholders at 0.08 Baht per share, totaling 85.44 million Baht, based on retained earnings in the company's financial statements as of September 30, 2025.
  • Certified as a member of Thailand's Private Sector Collective Action Against Corruption (CAC).
  • Received the "Best Health Business of the Year" award from the Thailand Top Entrepreneur Awards 2025, given to Thai entrepreneurs who stand out in management, innovation and sustainable business.
  • Received the "2025 Southeast Asian Stem Cell Banking & Regenerative Medicine Company of the Year" award from Frost & Sullivan, the global research and strategy consulting firm. It is the highest Best Practices Recognition, given to organizations that excel in innovation, operations, performance and positive impact on consumers and the healthcare system.
2025, 15th Anniversary: ATMPs Sandbox project launched